Medical System Network Co., Ltd. AI Stock Analysis
Want to see JP:4350 full AI Analyst Report?
Medical System Network Co., Ltd. (4350) AI Stock Analysis
Medical System Network Co., Ltd.
(TSE/TYO:4350)
The overall score is constrained by severe financial weaknesses, primarily the negative cash flow generation which poses a significant risk. The company's reasonable valuation and neutral technical picture provide some stability but are insufficient to offset the fundamental concerns regarding profitability and liquidity.
Medical System Network Co., Ltd. (4350) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.99B
- Dividend Yield
- 2.33%
- Average Volume (3M)
- 111.56K
- Price to Earnings (P/E)
- 17.4
- Beta (1Y)
- 0.35
- Revenue Growth
- 6.89%
- EPS Growth
- -55.21%
- Country
- Japan
- Employees
- 4,014
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Medical System Network Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Sapporo, Japan, and established in 1999, Medical System Network Co., Ltd. functions as a comprehensive provider within the healthcare industry. Its core business involves the distribution of pharmaceutical products to a diverse range...
Medical System Network Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. While revenue growth is steady and the balance sheet has deleveraged, profitability is deteriorating with declining margins. Most critically, operating and free cash flow turned sharply negative in the latest year, indicating severe liquidity strain.
Income Statement
40NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.23B | 132.19B | 122.39B | 115.36B | 109.55B | 106.69B |
| Gross Profit | 54.03B | 52.77B | 49.60B | 47.93B | 45.92B | 44.43B |
| EBITDA | 6.28B | 6.73B | 6.42B | 6.90B | 6.25B | 7.05B |
| Net Income | 870.00M | 1.07B | 1.26B | 1.86B | 1.61B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 79.29B | 80.10B | 70.63B | 68.19B | 66.27B | 62.98B |
| Cash, Cash Equivalents and Short-Term Investments | 7.28B | 7.74B | 8.46B | 8.27B | 8.14B | 8.20B |
| Total Debt | 30.51B | 37.67B | 29.79B | 29.18B | 30.52B | 29.57B |
| Total Liabilities | 62.16B | 62.68B | 54.28B | 52.97B | 51.78B | 49.69B |
| Stockholders Equity | 17.00B | 17.29B | 16.26B | 15.17B | 14.45B | 13.27B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -5.93B | 1.75B | 5.62B | 3.37B | 1.88B |
| Operating Cash Flow | 0 | -3.44B | 4.46B | 7.72B | 4.97B | 4.01B |
| Investing Cash Flow | 0 | -4.04B | -3.73B | -3.65B | -2.11B | -2.51B |
| Financing Cash Flow | 0 | 6.79B | -544.00M | -3.94B | -2.92B | -3.42B |
Medical System Network Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4350, the sentiment is Neutral. The current price of 516.00 is below the 20-day moving average (MA) of 524.80, above the 50-day MA of 513.99, and above the 200-day MA of 500.92, indicating a neutral trend. The MACD of 6.69 indicates Positive momentum. The RSI at 47.39 is Neutral, neither overbought nor oversold. The STOCH value of 25.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4350.
Medical System Network Co., Ltd. Peers Comparison
Overall Rating
JP:339181Outperform
JP:764969Neutral
JP:998969Neutral
JP:354962Neutral
JP:334959.9Neutral
JP:435048Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | JPY 1.11T | 19.56 | 7.13% | 1.88% | ― | ― | |
| 69Neutral | JPY 522.71B | 16.93 | 9.94% | 1.28% | 8.97% | -29.54% | |
| 69Neutral | JPY 449.92B | 14.48 | 11.15% | 3.39% | 4.32% | 0.18% | |
| 62Neutral | JPY 486.11B | 25.31 | ― | 0.29% | 12.54% | 15.87% | |
| 60Neutral | JPY 496.38B | 15.67 | ― | 1.29% | 8.99% | 3.61% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | JPY 15.66B | 17.37 | ― | 2.33% | 6.89% | -55.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4350 | Medical System Network Co., Ltd. | 516.00 | 31.09 | 6.41% | |
| JP:9989 | Sundrug Co | 3896.00 | -233.80 | -5.66% | |
| JP:7649 | Sugi Holdings Co | 1369.50 | -366.89 | -21.13% | |
| JP:3391 | TSURUHA Holdings | 2497.00 | -167.92 | -6.30% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6353.00 | -954.70 | -13.06% | |
| JP:3549 | KUSURI NO AOKI HOLDINGS CO.,LTD. | 5045.00 | 1159.08 | 29.83% |
Medical System Network Co., Ltd. Corporate Events
Medical System Network Grows Healthcare Network but Faces Profit Pressure in Q1 FY2027
Medical System Network reported consolidated net sales of 33.14 billion yen for the first quarter of the fiscal year ending March 2027, with operating profit at 120 million yen, reflecting rising personnel and system integration costs that weighed on...
Medical System Network Posts Higher Sales but Swings to Quarterly Loss, Keeps Dividend and Full-Year Guidance
Medical System Network reported consolidated net sales of ¥33.1 billion for the three months ended June 30, 2026, up 6.6% year on year, but profitability deteriorated sharply, with EBITDA down 26.9% and operating profit plunging 71.5%. The quarter sw...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 18, 2026
